Park Ha Biological Technology Co., Ltd. (BYAH) Cash Flow Statement
Where BYAH’s cash came from and went, FY2025
October 31, 2025 · U.S. dollars- Cash from operations
- $85,852 −91.1% vs FY2024
- Capital expenditures
- $88,822 3.5% of revenue
- Free cash flow
- −$2,970 −0.1% margin
- Returned to shareholders
- —
- Change in cash
- $3.2M cash at year-end $3.8M
Drawn to scale: where the cash came from and how it was used. Hover for values.
BYAH operating cash flow, capex and free cash flow
BYAH cash flow trends, FY2021–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$497,858FY2021 | $85,852FY2025 | — | |
| Capital expenditures | $12,907FY2021 | $88,822FY2025 | +62.0%/yr | |
| Free cash flow | −$510,765FY2021 | −$2,970FY2025 | — | |
| Free cash flow margin | −54.9%FY2021 | −0.1%FY2025 | +54.7 pts | |
| Operating cash flow / net income | 7.54FY2022 | 2.01FY2024 | −5.53 | |
| Stock-based compensation | $0FY2023 | $24.1MFY2025 | — | |
| Capex / revenue | 1.4%FY2021 | 3.5%FY2025 | +2.1 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BYAH cash flow by activity
BYAH net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
BYAH cash flow statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Operating activities | |||||
| Net income | −$24.4M | $478,561 | $852,042 | $191,298 | −$484,958 |
| Depreciation & amortization | $109,369 | $22,686 | $20,063 | $30,491 | $39,006 |
| Stock-based compensation | $24.1M | $0 | $0 | — | — |
| Change in working capital | −$91,475 | $254,405 | −$911,066 | $1.2M | −$53,569 |
| Other non-cash items | $362,511 | $204,818 | $165,498 | $46,754 | $1,663 |
| Cash from operating activities | $85,852 | $960,470 | $126,537 | $1.4M | −$497,858 |
| Investing activities | |||||
| Capital expenditures | −$88,822 | −$85,569 | −$22,676 | −$11,890 | −$12,907 |
| Investments (net) | — | −$508,143 | $1.0M | −$1.5M | −$12,907 |
| Acquisitions & other investing | −$484,105 | $85,569 | $22,676 | $11,890 | $12,907 |
| Cash from investing activities | −$572,927 | −$508,143 | $1.0M | −$1.5M | −$12,907 |
| Financing activities | |||||
| Net borrowing (repayment) | $6,930 | −$69,135 | −$715,190 | $135,503 | $235,559 |
| Shares issued | $4.3M | $500 | $38,265 | $534,149 | $263,068 |
| Other financing | −$549,060 | −$888,754 | $0 | $0 | $0 |
| Cash from financing activities | $3.7M | −$957,389 | −$676,925 | $669,652 | $498,627 |
| Summary | |||||
| Net change in cash | $3.2M | −$486,136 | $458,923 | $502,025 | −$8,442 |
| Cash at end of period | $3.8M | $547,498 | $1.0M | $574,711 | $72,686 |
| Free cash flow | −$2,970 | $874,901 | $103,861 | $1.4M | −$510,765 |
| Free cash flow margin | −0.1% | 36.7% | 4.2% | 74.5% | −54.9% |
| Capex / revenue | 3.5% | 3.6% | 0.9% | 0.6% | 1.4% |
| Operating cash flow / net income | — | 2.01 | 0.15 | 7.54 | — |
| Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | |
|---|---|---|---|---|---|
| Operating activities | |||||
| Net income | −$918,282 | −$459,141 | −$4.5M | −$2.3M | −$9.9M |
| Depreciation & amortization | $95,282 | $47,641 | $93,861 | $46,931 | $7,754 |
| Stock-based compensation | — | — | — | −$10.0M | $10.0M |
| Change in working capital | $454,868 | $192,027 | −$211,672 | −$214,429 | $120,197 |
| Other non-cash items | $254,405 | $162,609 | $4.5M | $12.3M | $60,479 |
| Cash from operating activities | −$113,727 | −$56,864 | −$159,581 | −$79,791 | $245,433 |
| Investing activities | |||||
| Capital expenditures | −$225,063 | −$112,533 | −$86,609 | −$43,306 | −$2,213 |
| Acquisitions & other investing | −$5.1M | −$2.6M | $2.8M | $1.4M | −$3.3M |
| Cash from investing activities | −$5.4M | −$2.7M | $2.7M | $1.3M | −$3.3M |
| Financing activities | |||||
| Shares issued | $0 | $0 | $0 | $0 | $0 |
| Other financing | $2.2M | $1.1M | −$97,834 | −$48,917 | $3.8M |
| Cash from financing activities | $2.2M | $1.1M | −$97,834 | −$48,917 | $3.8M |
| Summary | |||||
| Net change in cash | −$3.2M | — | $2.4M | — | $803,787 |
| Cash at end of period | $627,851 | $3.8M | $3.8M | $1.4M | $1.4M |
| Free cash flow | −$338,790 | −$169,397 | −$246,190 | −$123,097 | $243,220 |
| Free cash flow margin | −26.9% | −26.9% | −19.1% | −19.1% | 19.6% |
| Capex / revenue | 17.9% | 17.9% | 6.7% | 6.7% | 0.2% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
BYAH cash generation
In fiscal 2025 (ended October 31, 2025), Park Ha Biological Technology generated $0.1 million of cash from operations (down 91.1%) and spent $0.1 million on capital expenditures, leaving free cash flow of -$0.0 million, −0.1% of revenue. Cash and equivalents rose by $3.2 million over the year.
Related: BYAH income statement, BYAH balance sheet. See the BYAH stock overview for the latest quote and news.
BYAH cash flow FAQ
What is Park Ha Biological Technology's free cash flow?
Park Ha Biological Technology's free cash flow was -$0.0 million in fiscal 2025: $0.1 million of operating cash flow minus $0.1 million of capital expenditures It was $0.9 million a year earlier..
How much cash does Park Ha Biological Technology generate from operations?
Park Ha Biological Technology generated $0.1 million of cash from operating activities in fiscal 2025.
How much does Park Ha Biological Technology spend on capital expenditures?
Park Ha Biological Technology spent $0.1 million on capital expenditures in fiscal 2025, 3.5% of revenue, compared with $0.1 million the year before.